Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Date:4/14/2009

Expects to qualify for 180 days of sole marketing exclusivity

PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Hoffmann-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949.

Xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan has 117 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
2. Mylan Announces Clarinex(R) Settlement Agreement
3. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
5. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylan Announces Transition of Chief Financial Officer
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
8. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
9. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership College ... a thousand acres of soybeans, corn and wheat, and raises peas, sweet corn, baby ... for the fresh market. He also operates a roadside stand and raises broilers for ...
(Date:1/18/2017)... USA; SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... (PRWEB) January 18, 2017 -- Global public health organization NSF ... arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment ... water treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher ...
(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, a national, ... of Franchise Development, Paula Turner Pizarro, was recently featured on Fox Business Network's ... insights of top business leaders from across the globe, provides viewers an opportunity ...
(Date:1/18/2017)... Alexandria, VA (PRWEB) , ... January 18, 2017 , ... ... services in family, cosmetic and implants dentistry. His modern dental practice has two convenient ... Qureshi as a 2017 Top Rated Dentist for the Alexandria area. This ...
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SHANGHAI , Jan. 18, 2017 In ... of revolution, which is where the Upgrade of ... year of the 13th Five-Year Plan for Economic and Social ... (the 13th Five-Year Plan), and the state council of ... the "13th Five-Year" national strategic emerging industry development plan, identifying ...
(Date:1/18/2017)... , January 18, 2017 Ximbio, ... to share research resources, has opened its first North American ... ... marks an expansion for Ximbio following its launch in October ... Research Technology (CRT), the commercialization arm of the foundation Cancer ...
(Date:1/18/2017)... Authority Chinese Food and Drug Administration CSL ... Institute Food and Drug Administration FORT ... Glaxo Smith Klein GlaxoWellcome Global Influenza ... Immune Targeting Systems Indian Association of ... Johnson & Johnson Krka Pharmaceuticals Medicago ...
Breaking Medicine Technology: